Related Experiment Video
Updated: Jul 5, 2026
13:36
Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
Published on: May 6, 2015
10.8K
Defining a Simplified Process in Yeast for Production of Enveloped VLP Dengue Vaccine
Salomé de Sá Magalhães1, Stephen A Morris1, Shinta Kusumawardani2,3
1Department of Biochemical Engineering, Faculty of Engineering Sciences, University College London, London WC1E 6BT, UK.
Bioengineering (Basel, Switzerland)
|September 27, 2025
Summary
This study introduces Komagataella phaffii (Pichia pastoris) as a novel host for dengue vaccine production. This yeast platform offers efficient, cost-effective manufacturing of dengue viral-like particles (VLPs) for global health needs.
Area of Science:
- Biotechnology
- Vaccine Development
- Microbial Fermentation
Background:
- Dengue fever is a growing global health concern with millions of cases reported annually.
- Current dengue vaccine manufacturing faces challenges in efficiency, cost, and scalability.
- There is a critical need for innovative production methods to meet global demand.
Purpose of the Study:
- To explore an alternative process development pathway for dengue vaccine manufacturing.
- To utilize Komagataella phaffii (Pichia pastoris) as a host organism for dengue vaccine production.
- To address technical and operational challenges in scalable vaccine manufacturing.
Main Methods:
- Demonstrated the versatility of Komagataella phaffii for producing dengue viral-like particles (VLPs).
- Optimized culture processes using Design of Experiments (DoE) in small-scale bioreactors.
- Developed a novel purification platform for enveloped VLPs (eVLPs) and established biophysical characterization methods.
Main Results:
- Successfully produced dengue viral-like particles (VLPs) using the Komagataella phaffii platform.
- Optimized fermentation conditions for enhanced VLP yield and quality.
- Established a robust purification strategy for enveloped VLPs (eVLPs).
Conclusions:
- Komagataella phaffii presents a promising, scalable, and cost-effective platform for dengue vaccine manufacturing.
- The developed methods offer a foundation for addressing current vaccine production challenges.
- This research paves the way for efficient global supply of dengue vaccines.
More Related Videos
Related Concept Videos
01:30Lytic Cycle of Bacteriophages
Bacteriophages, also known as phages, are specialized viruses that infect bacteria. A key characteristic of phages is their distinctive “head-tail” morphology. A phage begins the infection process (i.e., lytic cycle) by attaching to the outside of a bacterial cell. Attachment is accomplished via proteins in the phage tail that bind to specific receptor proteins on the outer surface of the bacterium. The tail injects the phage’s DNA genome into the bacterial cytoplasm. In the lytic replication...
01:16Viral Replication: Lysogenic Cycle
The lysogenic cycle is a crucial viral replication strategy that allows bacteriophages to persist within host cells without immediately destroying them. This process is primarily observed in temperate phages, such as bacteriophage lambda (λ), which infects Escherichia coli. The cycle allows the viral genome to persist across bacterial generations while keeping host cells viable.Integration of the Viral GenomeUpon infection, bacteriophage lambda attaches to the bacterial surface and injects its...
01:28Pasteurization and Food Preservation
Pasteurization is a widely employed thermal processing technique designed to enhance the safety and shelf life of perishable food and beverages. By subjecting products to specific high temperatures for controlled durations, this method effectively inactivates pathogenic microorganisms and spoilage enzymes without significantly compromising sensory qualities. The technique has been pivotal in food safety management, especially for consumables susceptible to microbial contamination such as milk,...
01:23Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...